When combined with anti-PDL1, PDT-RT treatment results have shown tumor growth inhibition indices of primary and distant tumors as 99.5% and 98.0%, respectively, for CT26, and 94.7% and 92.2%, respectively, for SCC VII tumor models [91]. Here, DDX53 is linked to neoplasm.